![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, April 30, 2017 3:50:54 PM
April 28, 2017
Shares of Neurotrope Inc NTRP 24.24%, a clinical-stage biopharmaceutical company that develops therapies for the treatment of Alzheimer's and neurodegenerative diseases, shot higher by more than 15 percent early Friday morning.
Neurotrope announced it will be releasing Monday top-line data from a Phase 2 clinical trial exploring its therapy Bryostatin-1. The trial consists of 148 patients suffering from moderate to severe Alzheimer's Disease.
Bryostatin was developed at the Blanchette Rockefeller Neurosciences Institute and has shown promising signs of success even in patients with gene mutations.
What To Know
Benzinga had the opportunity to chat with Neurotrope CEO Dr. Susanne Wilke earlier this year.
Wilke explained there is a "current hypothesis" of treating the disease by focusing on neuronal loss. Instead, the company focuses on regenerative methods to replace lost synaptic networks that are consistently associated with the breakdown of human cognitive functions.
"In the current hypothesis," Wilke explained, "we take amyloid plaque and tau tangles - which kind of strangulate the neuron and then you have neuronal loss - as being causative for Alzheimer's. What we are saying is, maybe that is true, but it may not be causative."
Wilkes noted that before you get to neuronal loss, you probably will have synaptic loss and that's where Neurotrope's Bryostatin looks to be revolutionary.
Analyst's Take
Analysts at Aegis initiated coverage of Neurotrope in early April with a Buy rating and $31 price target under the belief that the company's Bryostatin could address several important pathologies of Alzheimer's
"If the Phase IIb trial is partially successful (meets some but not all of its endpoints) we believe it could still have therapeutic value in AD (Alzheimer's Disease) and other neurological diseases where cognitive function or development is affected," the analyst stated.
The stock traded recently at $15.61, up 3 percent on the day.
https://www.benzinga.com/general/biotech/17/04/9366312/neurotrope-alzheimers-phase-2-trial-data-coming-on-monday
Recent SNPX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:18 PM
- Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's • PR Newswire (US) • 12/06/2023 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/14/2023 10:05:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:23 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/03/2023 09:00:19 PM
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology • PR Newswire (US) • 11/02/2023 01:00:00 PM
- Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease • PR Newswire (US) • 09/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:55 PM
- Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study • PR Newswire (US) • 09/07/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:40 PM
- Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 07/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 12:55:57 PM
- Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience • PR Newswire (US) • 07/13/2023 01:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM